NASDAQ •
Healthcare •
Biotechnology •
Quote as of 07/15/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization25.18 mln
Float13.81 mln
Earnings Date08/19/2026
Piotroski F-Score
3
/ 9
Below average
Relative Strength
26
/ 100
Underperforming
Debt / Equity
0.00
Debt-free
ROE
-73.66
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
Marker Therapeutics is a US-based clinical-stage company focused on developing cancer treatments that harness the body's own immune cells to fight tumors. Their approach uses naturally occurring T cells ? without genetic modification ? that are trained to recognize and destroy cancer cells. The company is currently running early-stage clinical trials for treatments targeting blood cancers and pancreatic cancer. Founded in 1999 and based in Houston, Texas, the company was previously known as TapImmune before rebranding in 2018.
